Hi, I'm Richard Nesto, Chair of Cardiovascular Medicine, Co-Principal Investigator of the INTENSIVE (Intensive Insulin Therapy and Size of Infarct as a Validated Endpoint by Cardiac MRI) trial and a principal investigator of the NIH-supported BARI-2D, the largest study ever conducted on heart disease and diabetes.
As part of an internationally renowned academic medical center affiliated with Tufts University School of Medicine, Lahey Clinic's Heart and Vascular Center offers patients state-of-the-art care in a setting of clinical scholarship and research. Our main focus is on trials that directly impact patient care and expose patients to the latest advances in treatment.
Heart Attacks and Glucose Levels
Lahey Clinic has a major role in a landmark study examining whether lowering elevated glucose levels in patients with heart attacks reduces the risk of death or other serious heart damage. The study is called the INTENSIVE (Intensive Insulin Therapy and Size of Infarct as a Validated Endpoint by Cardiac MRI) trial. Patients at 60 medical centers in North and South America will participate in the two-year study, set to begin this month. Lahey Clinic is a vanguard center, which means it has a key role in developing and refining the final protocol for the trial.
We already know that people with high blood sugar do less well than those with normal sugar levels during or following a heart attack. What we are trying to determine in the INTENSIVE trial is if we lower the sugar with intravenous insulin, does this remove or lower the risk to the patient, resulting in less heart damage or lower likelihood of death?
In order to answer this question, researchers will be administering insulin to patients with high glucose levels during or following a heart attack. The administration of insulin will follow two strategies: some patients will be given a dose of intensive, long-acting insulin, while others will be given a lower dose of insulin, predominantly subcutaneously. Researchers will examine if this difference has an effect on outcome.
At 60 days following the heart attack, patients will have an MRI to examine the structure of the heart. If we find that insulin reduces the amount of heart damage, this will become a new standard of care in treating heart attacks. In addition, researchers are studying whether insulin has added therapeutic benefit.
Lahey's Cardiovascular Medicine Department has a long track record of involvement in landmark clinical trials evaluating different treatments for patients with diabetes, including the NIH-supported BARI-2D, the largest study ever conducted on heart disease and diabetes.
Identifying Plaques that Cause Heart Attacks
Heart attacks occur when the blood supply to the heart muscle itself is severely reduced or stopped due to the formation of plaque -- deposits of fat-like substances -- in one or more of the coronary arteries.
By using a number of light-based, imaging technologies, Lahey cardiologists are participating in pioneering studies to identify the plaques that put patients at a higher risk of heart attack. One of these technologies is near-infrared spectroscopy.